Lennox Hodgkinson of Nova Scotia was dressed all in Blackhawks gear for what his dad described as ...
DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public ...
The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...
Ann & Robert H. Lurie Children’s Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...
Ann & Robert H. Lurie Children's Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...
Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...
Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause of bacterial pneumonia for them. Indeed, it was the most frequently isolated ...